British medical device developer QuantuMDx (QMDx) and German life sciences company SCIENION have partnered to take QMDx's highly multiplexed nanowire array to market. This biosensor is a component of QMDx's flagship product Q-POC™, a handheld molecular diagnostic device that will provide results in 15 minutes for a few pounds at the patient's side.
Newcastle-Upon-Tyne, England and Berlin, Germany, June 9, 2015: QMDx utilises SCIENION's proprietary ultra-low volume liquid handling technologies to transfer biological material onto QMDx's novel biosensor. Each nanowire in the array is printed with molecular probes; with hundreds of nanowires in each silicon biosensor chip, the multiplexing potential is massive.
The companies' longstanding relationship was cemented with QMDx's purchase of SCIENION's sciFLEXARRAYER SX, and will continue to grow as the companies embark on a number of development projects to take the biosensor characterisation from R&D to mass manufacture.
The instrument is the newest fixture in QMDx's chemistry facility at the University of Newcastle upon Tyne's Chemical Nanoscience Laboratories.
QMDx's Head of Chemistry Dr Joseph Hedley said "The flexibility and ease of use of the sciFLEXARRAYER SX has enabled a rapid ramp up in QMDx's R&D activities, and we look forward to working with them on a number of exciting projects that will help bring this device to market."
"We're thrilled to be working with QuantuMDx" said Holger Eickhoff, CEO of SCIENION. "I look forward to our collaboration and believe that our work together will produce some fantastic developments that help foster some disruptive diagnostic innovations."
Please visit us at:
BIO International Convention 2015, June 15 - 18, 2015; Philadelphia, PA, USA. SCIENION at booth 1013-01 (part of the Berlin-Brandenburg booth)
QuantuMDx at booth 1127
About QuantuMDx Group
QuantuMDx Group is a multinational medical device developer headquartered in the United Kingdom, with subsidiary operations in the United States and Singapore. Expected for commercialisation in 2016, the company's flagship product Q-POC™ will empower overburdened healthcare systems worldwide with gold standard molecular diagnostics at a fraction of the cost of traditional testing. Q-POC's superior multiplexing capabilities will bring the power of precision medicine to health professionals globally, enabling immediate detection of antimicrobial resistance and subsequent 'right first time prescribing'. By geotagging and networking this disease data, QuantuMDx will build a real-time global pathogen monitoring system called the Internet of Life™. QuantuMDx was co-founded by CEO Elaine Warburton OBE, inventor and CSO Jonathan O'Halloran and CFO Julian Warburton. Fellow Board members include CMO Professor Sir John Burn, COO Dr Sam Whitehouse and President of QuantuMDx USA Paul Fitzpatrick. Prof Sanjeev Krishna chairs the Infectious Disease Advisory Committee. QuantuMDx has received grants from the UK and EU governments, and partnered with FIND in 2014.
SCIENION AG and its US subsidiary SCIENION US, Inc. provide systems and services for the contact-free printing of biological and chemical agents for diagnostics, pharmaceutics, veterinary, plant and food analytics and research. Addressing the dynamically increasing needs for miniaturization and multiplex analyses, SCIENION offers a unique technology portfolio that has been continuously expanded over one decade. SCIENION provides flexible solutions for research and development, wherein solutions for production purposes are customized. Systems and software are characterized by their versatility, precision and robustness. The company is a renowned specialist for ultra-low volume liquid handling, particularly for the handling of precious and sensitive compounds of biological or chemical origin. SCIENION's dispensers allow for contact-free and precise drop spotting in the pico- to micro-liter range and are optimally suited for microarray based analytics - such as for tests with DNA, oligonucleotides, peptides, proteins, antibodies, glycans or for dispensing cells onto various substrates. The company operates from two sites in Germany, Dortmund and Berlin, and has a subsidiary in New Jersey, USA.
QuantuMDx Group Ltd
Business Development and Marketing Officer, QuantuMDx Group Ltd
Phone 0870 803 1234